GLP-1 receptor agonists and dual incretin therapies are transforming diabetes care. These medications often produce significant and rapid improvements in glycemic control, sometimes lowering A1C levels faster than traditional treatments. However, clinicians have begun asking an important question: could rapid A1C reduction with GLP-1 therapy increase retinopathy risk in some …
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.